EntreMed, the University of New South Wales (UNSW), and Children's Cancer Institute Australia for Medical Research (CCIA) will together map pathways involved in the company’s lead anticancer compound. Panzem (2ME2) is being investigated in five separate Phase II trials.
"Associate Professor Maria Kavallaris and her team at CCIA and UNSW are leaders in the study of microtubule targeting agents,” says Mark R. Bray, Ph.D., EntreMed vp, research. “Through this research, we expect to determine the relative importance of known 2ME2 mechanisms as well as identify new protein targets and pathways whose functions are essential for the action of 2ME2 and its analogs. Further identification of these pathways may help in selecting the most effective clinical indications for 2ME2 treatment and may lead to the discovery of biomarkers useful for assessing 2ME2 activity in the clinic. Additionally, we hope to identify novel targets for new cancer drug development."
Research will be conducted at CCIA and UNSW under a grant awarded by the Australian Research Council.